Last updated: 11/03/2018 19:10:48
This product has been transferred to Novartis. GSK Clinical Study Register is no longer maintained for this study.
Drug Use Investigation of VOTRIENT Tablets
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
No longer a GSK study
No longer a GSK study
Trial overview
Official title: Drug Use Investigation of VOTRIENT Tablets
Trial description: This post-marketing surveillance (PMS) is conducted to collect safety and efficacy data in patients with STS who are treated with pazopanib tablets.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Progression-free survival
Timeframe: 1 year
Occurrence of adverse drug reactions
Timeframe: 1 year
Secondary outcomes:
Not applicable
Interventions:
Enrollment:
300
Primary completion date:
Not applicable
Observational study model:
Cohort
Time perspective:
Prospective
Clinical publications:
Not applicable
- Patients with STS
- Patients treated with pazopanib tablets
- None
Inclusion and exclusion criteria
Inclusion criteria:
- Patients with STS
- Patients treated with pazopanib tablets
Exclusion criteria:
- None
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
No longer a GSK study
Actual primary completion date
Not applicable
Actual study completion date
Not applicable
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website